BELVIN MARCIA (SVP, Chief Scientific Officer) sold 4.9% of their position (13.88K shares) of CYTOMX THERAPEUTICS, INC. on the open market
Open‑market sale worth $37.3K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 6/17/2025ACC: 0001610717-25-000235
Officer· SVP, Chief Scientific Officer
Since Feb 2026
-13.88K
Net shares
Net seller
$37.3K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
37.50K acquired · 51.38K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+37.50K
Price / share
—
Trade value
—
% of position
15.1%
6/13/2025
248.64K→286.14K
Common Stock
Direct
Shares
−13.88K
Price / share
$2.69
Trade value
$37.33K
% of position
4.9%
6/16/2025
286.14K→272.25K
Total
Net shares
+23.62K
Net value
-$37.33K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 6/13/2025 | M · Option Exercise | +37.50K | — | — | 15.1% | 248.64K | 286.14K |
| Common Stock Direct | 6/16/2025 | S · Sale | −13.88K | $2.69 | $37.33K | 4.9% | 286.14K | 272.25K |
| Total | +23.62K | -$37.33K | ||||||
Derivative Transactions1
Performance Stock Units
Direct
Converts to
Common Stock
37.50K shares
Shares
−37.50K
Strike price
Held after
0.00
Exercisable
—
6/13/2025
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Performance Stock Units Direct | Common Stock37.50K shares | 6/13/2025 | M · Option Exercise | −37.50K | — | 0.00 |